Epigenomics AG (EPGNF)
USD 0.79
(0.09%)
USD 0.79
(0.09%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 339.22 Thousand EUR | -30.06% |
| 2022 | 485 Thousand EUR | -92.18% |
| 2021 | 6.2 Million EUR | 636.7% |
| 2020 | 842 Thousand EUR | -25.16% |
| 2019 | 1.12 Million EUR | -26.61% |
| 2018 | 1.53 Million EUR | -17.76% |
| 2017 | 1.86 Million EUR | -55.63% |
| 2016 | 4.2 Million EUR | 101.78% |
| 2015 | 2.08 Million EUR | 38.16% |
| 2014 | 1.5 Million EUR | -5.1% |
| 2013 | 1.58 Million EUR | 52.84% |
| 2012 | 1.03 Million EUR | -27.7% |
| 2011 | 1.43 Million EUR | -19.59% |
| 2010 | 1.78 Million EUR | -58.05% |
| 2009 | 4.26 Million EUR | 64.73% |
| 2008 | 2.58 Million EUR | 0.74% |
| 2007 | 2.56 Million EUR | -26.74% |
| 2006 | 3.5 Million EUR | -63.48% |
| 2005 | 9.59 Million EUR | 20.97% |
| 2004 | 7.93 Million EUR | -26.41% |
| 2003 | 10.77 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 FY | 339.22 Thousand EUR | -30.06% |
| 2023 Q4 | 68.11 Thousand EUR | 0.0% |
| 2023 Q2 | 70 Thousand EUR | -47.76% |
| 2023 Q1 | 134 Thousand EUR | 35.35% |
| 2023 Q3 | 68.11 Thousand EUR | -2.69% |
| 2022 Q3 | 145 Thousand EUR | 15.08% |
| 2022 Q1 | 115 Thousand EUR | -36.46% |
| 2022 Q4 | 99 Thousand EUR | -31.72% |
| 2022 FY | 485 Thousand EUR | -92.18% |
| 2022 Q2 | 126 Thousand EUR | 9.57% |
| 2021 Q3 | 5.79 Million EUR | 4856.41% |
| 2021 Q4 | 181 Thousand EUR | -96.88% |
| 2021 FY | 6.2 Million EUR | 636.7% |
| 2021 Q1 | 106 Thousand EUR | -64.78% |
| 2021 Q2 | 117 Thousand EUR | 10.38% |
| 2020 FY | 842 Thousand EUR | -25.16% |
| 2020 Q3 | 219 Thousand EUR | 163.86% |
| 2020 Q1 | 239 Thousand EUR | -14.03% |
| 2020 Q2 | 83 Thousand EUR | -65.27% |
| 2020 Q4 | 301 Thousand EUR | 37.44% |
| 2019 FY | 1.12 Million EUR | -26.61% |
| 2019 Q1 | 331 Thousand EUR | 51.83% |
| 2019 Q2 | 348 Thousand EUR | 5.14% |
| 2019 Q3 | 168 Thousand EUR | -51.72% |
| 2019 Q4 | 278 Thousand EUR | 65.48% |
| 2018 Q3 | 544 Thousand EUR | 17.75% |
| 2018 FY | 1.53 Million EUR | -17.76% |
| 2018 Q1 | 309 Thousand EUR | -68.79% |
| 2018 Q2 | 462 Thousand EUR | 49.51% |
| 2018 Q4 | 218 Thousand EUR | -59.93% |
| 2017 FY | 1.86 Million EUR | -55.63% |
| 2017 Q1 | 281 Thousand EUR | -84.22% |
| 2017 Q3 | 346 Thousand EUR | 40.65% |
| 2017 Q2 | 246 Thousand EUR | -12.46% |
| 2017 Q4 | 990 Thousand EUR | 186.13% |
| 2016 Q2 | 1.26 Million EUR | 327.12% |
| 2016 FY | 4.2 Million EUR | 101.78% |
| 2016 Q4 | 1.78 Million EUR | 106.13% |
| 2016 Q3 | 864 Thousand EUR | -31.43% |
| 2016 Q1 | 295 Thousand EUR | -61.08% |
| 2015 Q3 | 471 Thousand EUR | -3.29% |
| 2015 Q4 | 758 Thousand EUR | 60.93% |
| 2015 Q2 | 487 Thousand EUR | 32.7% |
| 2015 Q1 | 367 Thousand EUR | -10.92% |
| 2015 FY | 2.08 Million EUR | 38.16% |
| 2014 Q1 | 407 Thousand EUR | -35.09% |
| 2014 FY | 1.5 Million EUR | -5.1% |
| 2014 Q4 | 412 Thousand EUR | 45.07% |
| 2014 Q3 | 284 Thousand EUR | -29.88% |
| 2014 Q2 | 405 Thousand EUR | -0.49% |
| 2013 Q2 | 343 Thousand EUR | -3.38% |
| 2013 Q3 | 263 Thousand EUR | -23.32% |
| 2013 Q4 | 627 Thousand EUR | 138.4% |
| 2013 FY | 1.58 Million EUR | 52.84% |
| 2013 Q1 | 355 Thousand EUR | -3.27% |
| 2012 Q2 | 156 Thousand EUR | -35.8% |
| 2012 FY | 1.03 Million EUR | -27.7% |
| 2012 Q1 | 243 Thousand EUR | 24.62% |
| 2012 Q3 | 272 Thousand EUR | 74.36% |
| 2012 Q4 | 367 Thousand EUR | 34.93% |
| 2011 FY | 1.43 Million EUR | -19.59% |
| 2011 Q1 | 621 Thousand EUR | 37.69% |
| 2011 Q2 | 364 Thousand EUR | -41.38% |
| 2011 Q3 | 257 Thousand EUR | -29.4% |
| 2011 Q4 | 195 Thousand EUR | -24.12% |
| 2010 Q1 | 621 Thousand EUR | -38.64% |
| 2010 Q4 | 451 Thousand EUR | 24.24% |
| 2010 Q3 | 363 Thousand EUR | 3.42% |
| 2010 Q2 | 351 Thousand EUR | -43.48% |
| 2010 FY | 1.78 Million EUR | -58.05% |
| 2009 Q3 | 1.17 Million EUR | 40.36% |
| 2009 FY | 4.26 Million EUR | 64.73% |
| 2009 Q1 | 1.24 Million EUR | 0.0% |
| 2009 Q2 | 835 Thousand EUR | -32.77% |
| 2009 Q4 | 1.01 Million EUR | -13.65% |
| 2008 FY | 2.58 Million EUR | 0.74% |
| 2007 FY | 2.56 Million EUR | -26.74% |
| 2006 FY | 3.5 Million EUR | -63.48% |
| 2005 FY | 9.59 Million EUR | 20.97% |
| 2004 FY | 7.93 Million EUR | -26.41% |
| 2003 FY | 10.77 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| American Bio Medica Corporation | 913 Thousand USD | 62.845% |
| Arrayit Corporation | 4.37 Million USD | 92.25% |
| Atlantic International Corp. | - USD | -Infinity% |
| Biocept, Inc. | 25.85 Million USD | 98.688% |
| Bioqual, Inc. | 58.59 Million USD | 99.421% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 15.29 Million USD | 97.782% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 7.38 Billion USD | 99.995% |
| HTG Molecular Diagnostics, Inc. | 6.36 Million USD | 94.671% |
| iMD Companies, Inc. | - USD | -Infinity% |
| IDenta Corp. | 1.05 Million USD | 67.742% |
| Interpace Biosciences, Inc. | 40.21 Million USD | 99.156% |
| Integrative Health Technologies, Inc. | 447.49 Thousand USD | 24.195% |
| InVitro International | 792.62 Thousand USD | 57.202% |
| Lumos Diagnostics Holdings Limited | 11.13 Million USD | 96.952% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 7.22 Million USD | 95.304% |
| NovelStem International Corp. | 12 Thousand USD | -2726.892% |
| Optigenex Inc. | 465.97 Thousand USD | 27.2% |
| PharmChem, Inc. | 6.01 Million USD | 94.358% |
| Proteome Sciences plc | 6.4 Million USD | 94.7% |
| Response Genetics, Inc | 18.04 Million USD | 98.12% |
| Rennova Health, Inc. | 13.03 Million USD | 97.398% |
| RushNet, Inc. | 1.78 Million USD | 81.026% |
| ScreenPro Security Inc. | 1.91 Million USD | 82.277% |
| Stella Diagnostics Inc. | - USD | -Infinity% |
| StageZero Life Sciences Ltd. | 3.79 Million USD | 91.061% |
| Todos Medical Ltd. | 7.69 Million USD | 95.592% |